Life Science Leader Chief Editor Blog Header image Life Science Leader Chief Editor Blog Header image

The Essentials Of Your BIO 2018 Educational Session Proposal
The Essentials Of Your BIO 2018 Educational Session Proposal Next week, BIO will invite biopharmaceutical industry experts to submit educational topic session proposals for the 2018 BIO International Convention in Boston, June 4 - 7. The 2018 call for sessions and speakers opens on Thursday, September 14, and closes on Thursday, October 12, 2017. As I have (once again) agreed to serve as a BIO educational program planning committee co-chair, I have a vested interest in its success. My goal in helping...  Continue Reading...
My Top 10 Quotes From David Hung, Axovant Sciences CEO
My Top 10 Quotes From David Hung, Axovant Sciences CEO Forbes once called Merck’s Ken Frazier a “quote machine,” but I’d say David Hung is just as deserving of that moniker. I interviewed Hung, the new CEO of Axovant Sciences, at the BIO conference in June, and throughout our discussion I found myself smiling. Hung, who saw the company he founded, Medivation, be acquired by Pfizer for $14.3 billion, will be the subject of a Life Science Leader magazine exclusive feature in...  Continue Reading...
What Do Partnering For Cures And A GSK Plant Tour Have In Common?
What Do Partnering For Cures And A GSK Plant Tour Have In Common? In July I had two interesting opportunities. The first was on July 12, 2017 when I attended the Partnering For Cures (Twitter hashtag #FCP4C) conference in Boston. The second took place on July 19, when I got to tour GSK’s vaccine manufacturing facility in Marietta, PA. And while you might not think that a biopharmaceutical conference and a manufacturing facility would have much in common, in actuality they do, as both are focused on...  Continue Reading...
Did You See Any Breakthroughs At BIO?
Did You See Any Breakthroughs At BIO? As usual, the BIO International 2017 Convention was a top-shelf event. This year’s show theme was, “breakthroughs.” And while I didn’t see a single breakthrough therapeutic take center stage at this year’s event, there were still a significant number of them worth noting. For example, in the first can’t-miss session listed in my pre-BIO blog, attendance nearly broke through the walls — literally. Not...  Continue Reading...
How Has Biopharma Arrived At Its Current Lose-Lose Situation?
How Has Biopharma Arrived At Its Current Lose-Lose Situation? Drug Sales Reel Amid Probe Into Charities. This was the headline of Jonathan Rockoff’s June 12, 2017, Wall Street Journal article that points out how sales for two U.S. “blockbuster prostate-cancer drugs” (i.e., J&J’s Zytiga and Pfizer’s Xtandi) were down (i.e., 14 and 11 percent respectively) for the first quarter from a year previous. Apparently there are two contributing factors that explain this drop in...  Continue Reading...
3 Can’t Miss Educational Sessions At BIO 2017
3 Can’t Miss Educational Sessions At BIO 2017 As we get closer to one of our industry’s biggest annual gatherings, the BIO International 2017 Convention in San Diego, June 19 – 22, I have begun to pin down my schedule for which educational sessions I plan to attend. For me, this has always been a challenge, as BIO has so much great educational content. And with many of the educational sessions overlapping, I find I have to pick and choose where I want to be, often with at least...  Continue Reading...
Biopharmaceutical Industry CEO Of The Year — An Update
Biopharmaceutical Industry CEO Of The Year — An Update On April 25, 2017, I posted a blog asking the question, Who Is The Biopharmaceutical CEO Of The Year. In the blog, I included a link to a short survey. Our goal was twofold: see if there was enough interest in continuing to pursue such an award, and generate an initial list of names that would be in contention. Thus far, 10 names have been submitted via dozens of submissions, but it’s too early for us to make any decisions or conclusions...  Continue Reading...
Biopharma Innovation — Value At Any Price?
Biopharma Innovation — Value At Any Price? In March I attended The Conference Forum’s R&D Leadership Summit. One of the panels that provided a great deal of insight involved executives discussing how to assess and create value for patients, payors, regulators, and society. This event employs the Chatham House Rule, which means “Neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed.” Despite not being able to...  Continue Reading...
Are You Ready For BIO 2017 In San Diego?
Are You Ready For BIO 2017 In San Diego? With the BIO International 2017 Convention being just seven weeks away, your preparations as an attendee should be well underway. But until they arrive on-site, many people often overlook deciding what educational sessions to attend. And while BIO attendees can afford to take such an approach, speakers certainly cannot. As the past BIO educational planning co-chair, I can attest that a lot of work goes into pulling off a high-quality educational ...  Continue Reading...
Who Is The Biopharmaceutical Industry CEO Of The Year?
Who Is The Biopharmaceutical Industry CEO Of The Year? I’ve been thinking, if you were going to name someone to be the biopharmaceutical industry CEO of the year, who would it be? But even more important than the who is the why. What criteria would you use? I’ve been looking through a bunch of articles that list top influencers for our industry, and the criterion for inclusion seems pretty subjective. There are media outlets that employ a variety of objective measures (i.e., company...  Continue Reading...